A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
José Ramón SantosPere DomingoJoaquín PortillaFélix GutiérrezArkaitz ImazHelem VilchezAdrià CurranNieves Valcarce-PardeiroAntoni PayerasEnrique Bernal-MorellMarta Montero-AlonsoMiguel YzusquiBonaventura ClotetSebastià VidelaJosé MoltóRoger ParedesPublished in: Open forum infectious diseases (2023)
ClinicalTrials.gov (NCT03683524).